Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04424511
Other study ID # LAKANA trial
Secondary ID INV-003354
Status Recruiting
Phase Phase 3
First received
Last updated
Start date October 15, 2020
Est. completion date December 31, 2024

Study information

Verified date November 2023
Source Tampere University
Contact Per Ashorn, MD, PhD
Phone 407280345
Email per.ashorn@tuni.fi
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The LAKANA trial will assess the impact on mortality and other health outcomes of quarterly and biannual azithromycin mass drug administration (MDA) when delivered to 1-11-month (29-364 days) old infants in a high-mortality setting where malaria is holoendemic but there is also a functioning seasonal malaria chemoprevention (SMC) program in place. The long-term goal is to more precisely define the role of mass azithromycin treatments as an intervention for reducing childhood mortality, and to determine the most effective treatment regimen. The main study hypotheses in terms of mortality effect are: i) Biannual azithromycin MDA to 1-11 month old infants reduces their mortality, ii) Quarterly azithromycin MDA to 1-11 month old infants reduces their mortality, iii) Quarterly azithromycin MDA has a bigger mortality effect than biannual MDA.


Description:

Mass drug administration (MDA) of azithromycin has been shown to reduce under-5 mortality in some but not all sub-Saharan African settings. Because of the observed heterogeneity and possible effect modification by SMC or other co-interventions, further trials in new settings are needed in order to make evidence-based public health recommendations about the use of this treatment. The objectives of the LAKANA trial are: - To evaluate the impact of two azithromycin MDA regimens on infant mortality and other health outcomes, when provided in a rural West-African high-mortality context with an ongoing seasonal malaria chemoprevention program. - To evaluate the effect of alternative MDA frequencies on antimicrobial resistance (AMR) and host microbiota composition. - To test hypotheses that azithromycin MDA eliminates malaria parasitaemia and reduces systemic and intestinal inflammation in asymptomatic children and to collect and store biological samples for assessing other possible mechanisms of azithromycin effect. - To investigate the feasibility of alternative azithromycin MDA strategies, including economic analysis. The LAKANA trial will be conducted in 1150 villages from 7-10 health districts in the Kayes, Kita and Koulikoro regions of Mali. LAKANA is a cluster-randomized, placebo-controlled, double-blinded, parallel-group, three-arm clinical trial, with adaptive design. Participating villages will be randomly allocated to three different intervention groups in a ratio of 3 : 2 : 4 (control : azithromycin quarterly : azithromycin biannually). Within each participating village, consenting households will be visited quarterly (at 3-month intervals), nine times. At the first eight of these visits, 1-11-month-old eligible infants (age 29-364 days), for whom there is a consent for study drug provision, will be given a single dose of study drug (azithromycin mixture or respective placebo mixture). Mortality and serious adverse events (SAEs) data will be collected, and mortality-related questions answered using data from all the included 1150 villages. Mixed-effect Poisson regression model will be used to estimate the intervention effects on mortality, with random intercepts for the clusters. The investigators will explore effect modification by testing for interaction between the MDA intervention and the following variables: - Infant age at the time of MDA (1-5 months vs 6-11 months) - Infant weight-for-age at the time of MDA - Infant sex - Season of MDA dosing and time since the last SMC - Cluster level coverage of SMC - Cluster level baseline mortality (established at first census) - Cluster and individual level coverage and number of administered azithromycin MDA doses - District of residence - Distance from the nearest health facility - Household asset or income index - Household WASH index The investigators will address the other study questions using a smaller separate secondary sample of 59 villages located around four selected health centers close to the city of Kita and a similar number of villages closer to Bamako, i.e. in Koulikoro or Kati (tertiary sample).


Recruitment information / eligibility

Status Recruiting
Enrollment 100000
Est. completion date December 31, 2024
Est. primary completion date December 31, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 29 Days to 364 Days
Eligibility Inclusion Criteria: On a cluster (village) level: 1. Location within Kayes, Kita, or Koulikoro region of Mali 2. Considered accessible and safe by the local health authorities and research team 3. Considered non-urban by the local health authorities and research team 4. Permission from community leadership On a household level (for trial enrollment): 1. Location within a cluster that is included in the study 2. Verbal consent from a head of household or an adult authorized by her / him On a child level (for receiving study medication): 1. Residence in a household enrolled in the trial 2. Age between 29 and 364 days 3. Verbal consent from at least one caregiver Exclusion Criteria: On child level (for not receiving study medication): 1. Weight below 3.0 kg 2. Known allergy to macrolides, as judged by a caregiver report of the infant experiencing an adverse reaction after oral ingestion of medication, which was deemed likely to be a macrolide by the interviewing data collector.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Placebo
Placebo mixture will be administered as a single dose in oral suspension form for children 1-11 months of age. Weight-based dosing will be used: single-dose of 0.5 ml / kg child weight.
Azithromycin
Azithromycin will be administered as a single dose in oral suspension form for children 1-11 months of age. Weight-based dosing will be used: single-dose of 0.5 ml (20 mg) / kg child weight.

Locations

Country Name City State
Mali Center for Vaccine Development CVD-Mali Bamako

Sponsors (7)

Lead Sponsor Collaborator
Tampere University Bill and Melinda Gates Foundation (Funder), Center for Vaccine Development CVD-Mali, Bamako, Mali, Duke-NUS Graduate Medical School, Pfizer Inc. (Provider of study drugs), Tro Da Ltd, UK, University College London Hospitals

Country where clinical trial is conducted

Mali, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mortality Mortality rate (deaths per 1,000 years at risk) among children 1-11 months of age. 3-month time interval (total of 8 intervals per cluster)
Secondary Morbidity Morbidity (14-day period prevalence of fever with respiratory symptoms (ARI), fever without respiratory symptoms (malaria), and diarrhea) in children aged 4-14 months assessed in each participating cluster (village) from the secondary outcome sample. 3-month time interval (total of 8 intervals per cluster)
Secondary Length-for-age Z-score Length-for-age Z-score in 6-8 and 12-14 months old children from the secondary outcome sample. Length measures will be taken at 15, 18, and 21 months after the enrollment of the village into the trial. Length-for-age Z-score will be calculated using the WHO Child Growth Standards. 3-month time interval (total of 3 intervals per cluster)
Secondary Weight-for age Z-score Weight-for age Z-score in 6-8 and 12-14 months old children from the secondary outcome sample. Weight measures will be taken at 15, 18, and 21 months after the enrollment of the village into the trial. Weight-for-age Z-score will be calculated using the WHO Child Growth Standards. 3-month time interval (total of 3 intervals per cluster)
Secondary Weight-for-length Z-score Weight-for-length Z-score in 6-8 and 12-14 months old children from the secondary outcome sample. Length and weight measures will be taken at 15, 18, and 21 months after the enrollment of the village into the trial. Weight-for-length Z score will be calculated using the WHO Child Growth Standards. 3-month time interval (total of 3 intervals per cluster)
Secondary Mid-upper arm circumference Mid-upper arm circumference in 6-8 and 12-14 months old children from the secondary outcome sample. Measures will be taken at 15, 18, and 21 months after the enrollment of the village into the trial. 3-month time interval (total of 3 intervals per cluster)
Secondary Percentage of moderate or severe stunting Percentage of moderate or severe stunting (length-for-age Z-score < -2 / -3) in 6-8 and 12-14 months old children from the secondary outcome sample. 3-month time interval (total of 3 intervals per cluster)
Secondary Percentage of moderate or severe wasting Percentage of moderate or severe wasting (Weight-for-length Z-score < -2 / -3) in 6-8 and 12-14 months old children from the secondary outcome sample. 3-month time interval (total of 3 intervals per cluster)
Secondary Prevalence of phenotypic and genotypic macrolide resistance Prevalence of phenotypic and genotypic macrolide resistance among E. coli strains isolated from stool samples or S. pneumoniae strains isolated from nasopharyngeal swabs among among 4-14-month-old children, at one year after the MDA intervention has stopped (i.e., 36 months after MDA 1, the baseline).
Genetic markers of azithromycin and other antibiotic resistance (resistome) of intestinal microbiota among 4-14-month-old children, at one year after the MDA intervention has stopped (i.e., 36 months after MDA 1, the baseline).
(secondary outcome sample).
12-month time interval (total of 3 intervals per cluster)
Secondary Prevalence of phenotypic and genotypic macrolide resistance Prevalence of phenotypic and genotypic macrolide resistance among E. coli strains isolated from stool samples or S. pneumoniae strains isolated from nasopharyngeal swabs among 49-59-month-old children, at 24 months after village enrolment to the trial, i.e., after 8 rounds of MDA. (secondary outcome sample). 12-month time interval (total of 3 intervals per cluster)
Secondary Prevalence of phenotypic and genotypic AMR resistance to other "ACCESS" group antibiotics Prevalence of phenotypic and genotypic AMR against other antibiotics categorised by the World Health Organization (WHO) into "ACCESS" group, among azithromycin-resistant E. coli strains isolated from stool samples or azithromycin-resistant S. pneumoniae strains isolated from nasopharyngeal swabs (secondary outcome sample). 12-month time interval (total of 3 intervals per cluster)
Secondary Blood C-reactive protein concentration Biological samples taken from 4-11 months old infants to assess effect of azithromycin MDA on systemic inflammation (blood C-reactive protein concentration) (secondary outcome sample). Biological samples taken before and 14 days after the fourth MDA round, 9 months after enrollment.
Secondary Blood malaria parasitemia and hemoglobin concentration Biological samples taken from 4-11 months old infants to assess effect of azithromycin MDA on malaria prevalence and blood hemoglobin concentration (secondary outcome sample). Biological samples taken before and 14 days after the fourth MDA round, 9 months after enrollment.
Secondary Fecal neopterin, myeloperoxidase, and alpha-1-antitrypsin concentrations Biological samples taken from 4-11 months old infants to assess effect of azithromycin MDA on intestinal inflammation (secondary outcome sample). Biological samples taken before and 14 days after the fourth MDA round, 9 months after enrollment.
Secondary Incidence of Adverse events Incidence of adverse events within 14 days of study drug administration. Data collected from 4-11 months old infants at 9 months after enrollment (secondary outcome sample). 3-month time interval
Secondary Incidence of Serious Adverse events Incidence of serious adverse events (Death, life-threatening event, hospitalization, and other serious events as judged by a study physician) within 14 days of study drug administration, among 1-11 months old infants. within 14 days after MDA round.
Secondary Mortality in children aged 12-59 month Mortality rate (deaths per 1000 years at risk) among children who were 12-59 month old when the latest azithromycin MDA took place in their village of residence. 3-month time interval (total of 8 intervals per cluster)
Secondary Percentage of guardians and health care workers reporting MDA acceptable Data collected through interviews of guardians and health care workers to assess acceptability of MDA. 24 months after enrollment
Secondary Percentage of the study population reached with MDA Data collected on MDA distribution and through interviews of guardians and health care workers to assess equity of MDA. 24 months after enrollment
Secondary Cost and Cost-effectiveness of the intervention Data collected on MDA distribution to assess the economic aspects of MDA.The effectiveness will be determined by the trial outcome - both the primary outcome of mortality and the secondary outcomes of morbidity and possible AMR effects. The effectiveness will be expressed in different units such as deaths averted, or disability adjusted life years (DALYs). 24 months after enrollment
See also
  Status Clinical Trial Phase
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT04092465 - Outcomes of Surgical Resection After Induction Treatment in Non-Small Cell Lung Cancer (SRaIT)
Completed NCT03296423 - Bacillus Calmette-guérin Vaccination to Prevent Infections of the Elderly Phase 4
Not yet recruiting NCT04900610 - The Effect of Vitamin K2 Supplementation on Arterial Stifness and Cardiovascular Events in PEritonial DIAlysis N/A
Completed NCT04149873 - Effectness of Treatment With Mechanical Insufflation-Exsufflation N/A
Completed NCT05905042 - Follow-up of Recovery Condition in Survivors of Acute Respiratory Distress Syndrome
Completed NCT00527774 - Effect of HCV Infection on Insulin Resistance and Malnutrition-inflammation Complex Syndrome in Regular Hemodialysis Patients N/A
Completed NCT00518856 - Lufwanyama Neonatal Survival Project N/A
Completed NCT06408636 - Prognostic Role of LA Strain in Acute Myocardial Infarction
Completed NCT06051526 - The African Critical Illness Outcomes Study
Recruiting NCT05055089 - Short- and Medium-term Results of New Generation Aortic
Active, not recruiting NCT04132492 - AGNES - Aging Nephropathy Study, a Prospective Observational Cohort of Chronic Kidney Disease in Elderly Patients
Completed NCT03885206 - Effectiveness and Clinical Outcomes of Municipal Acute Wards Versus a General Hospital N/A
Completed NCT05573659 - Capillary Refill Time Calculated With a Video-assisted Method Has a Better Reproducibility Than Visual Method in Critically Ill Patients N/A
Withdrawn NCT03245658 - The Effect of Cannabis in Pancreatic Cancer Phase 2
Recruiting NCT04094428 - Burden, Mortality and Supply Costs in Intensive Care Unit Patients
Completed NCT01631799 - Outcome of Patients After Total Knee Replacement: A Comparison of Femoral Nerve Block and Epidural Anesthesia N/A
Completed NCT00244673 - Randomized Study of Not Giving Diphteria-tetanus-pertussis Vaccination With or After Measles Vaccination Phase 4
Completed NCT03378843 - Spermidine Intake and All-cause Mortality N/A
Completed NCT04032288 - Establish a Prospective Registration System of ARDS Patients for Improving Quality of Care